查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1538352

創傷後頭痛市場報告：2030 年趨勢、預測與競爭分析

Post-Traumatic Headache Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

外傷後頭痛的趨勢與預測

預計 2024 年至 2030 年，全球創傷後頭痛 (PTH) 市場將以 4.3% 的複合年成長率成長。該市場的主要促進因素是創傷性腦損傷盛行率的上升、新治療方案的創造以及對 PTH 認知的提高。全球創傷後頭痛市場的未來看起來充滿希望，醫院藥局、零售藥局和線上藥局市場充滿機會。

按部位分類的外傷後頭痛

該研究包括按藥物類型、分銷管道、給藥途徑和地區分類的全球創傷後頭痛市場預測。

創傷後頭痛市場洞察

Lucintel 預測，偏頭痛專用已停產曲坦類藥物預計將在預測期內強勁成長。

在這個市場中，線上藥局預計將呈現更高的成長。

預計北美在預測期內將經歷最高的成長。

常問問題

Q1.市場成長預測是多少：

A1. 2024 年至 2030 年，全球創傷後頭痛市場預計將以 4.3% 的複合年成長率成長。

Q2. 影響市場成長的關鍵促進因素是：

A2. 該市場的主要驅動力是創傷性腦損傷盛行率的上升、新治療方案的創造以及人們對 PTH 的認知不斷提高。

Q3.市場的主要細分市場是：

A3. 創傷後頭痛市場前景廣闊，醫院藥局、零售藥局和線上藥局市場充滿機會。

Q4.市場的主要企業是：

A4.與相關企業如下：

  • Novartis
  • Johnson & Johnson Health Care Systems
  • Impax Laboratories
  • AstraZeneca
  • Grunenthal
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Pfizer
  • Merck & Co
  • Aralez Pharmaceuticals

Q5.未來最大的細分市場是什麼？

A5.Lucintel 預計口服製劑在預測期內將經歷最高成長。

Q6.未來五年預計哪些地區的市場成長最大？

A6. 預計北美地區在預測期內將出現最高成長。

Q7. 可以客製化報告嗎？

A7。

目錄

第1章執行摘要

第2章全球創傷後頭痛市場：市場動態

  • 簡介、背景、分類
  • 供應鏈
  • 產業促進因素與挑戰

第3章 2018-2030年市場趨勢及預測分析

  • 宏觀經濟趨勢（2018-2023）與預測（2024-2030）
  • 全球創傷後頭痛市場趨勢（2018-2023）與預測（2024-2030）
  • 按藥物類型分類的全球創傷後頭痛市場
    • 發炎藥
    • 乙醯水楊酸
    • 乙醯胺酚
    • 偏頭痛特異性停藥曲坦類藥物
  • 按分銷管道分類的全球創傷後頭痛市場
    • 醫院藥房
    • 零售藥房
    • 網路藥房
  • 按途徑的全球創傷後頭痛市場
    • 口服劑
    • 注射

第4章 2018-2030年區域市場趨勢及預測分析

  • 全球創傷後頭痛市場（按地區）
  • 北美創傷後頭痛市場
  • 歐洲創傷後頭痛市場
  • 亞太創傷後頭痛市場
  • 其他地區外傷後頭痛市場

第5章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析

第6章 成長機會與策略分析

  • 成長機會分析
    • 按藥物類型分類的全球創傷後頭痛市場成長機會
    • 全球創傷後頭痛市場成長機會（按分銷管道）
    • 途徑的全球創傷後頭痛市場成長機會
    • 全球創傷後頭痛市場成長機會（按地區）
  • 全球創傷後頭痛市場的新興趨勢
  • 戰略分析
    • 新產品開發
    • 全球創傷後頭痛市場產能擴張
    • 全球創傷後頭痛市場的合併、收購和合資企業
    • 認證和許可

第7章主要企業概況

  • Novartis
  • Johnson & Johnson Health Care Systems
  • Impax Laboratories
  • AstraZeneca
  • Grunenthal
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Pfizer
  • Merck & Co
  • Aralez Pharmaceuticals
簡介目錄

Post-Traumatic Headache Trends and Forecast

The future of the global post-traumatic headache market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets. The global post-traumatic headache market is expected to grow with a CAGR of 4.3% from 2024 to 2030. The major drivers for this market are rising prevalence of traumatic brain injuries, creation of novel treatment alternatives, and increasing recognition of PTH.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Post-Traumatic Headache by Segment

The study includes a forecast for the global post-traumatic headache by drug type, distribution channel, route of administration, and region.

Post-Traumatic Headache Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Anti-Inflammatory Drug
  • Acetylsalicylic Acid
  • Acetaminophen
  • Migraine-Specific Abortant Triptan

Post-Traumatic Headache Market by Distribution Channel [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Post-Traumatic Headache Market by Route of Administration [Shipment Analysis by Value from 2018 to 2030]:

  • Oral
  • Injectable

Post-Traumatic Headache Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Post-Traumatic Headache Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies post-traumatic headache companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the post-traumatic headache companies profiled in this report include-

  • Novartis
  • Johnson & Johnson Health Care Systems
  • Impax Laboratories
  • AstraZeneca
  • Grunenthal
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Pfizer
  • Merck & Co
  • Aralez Pharmaceuticals

Post-Traumatic Headache Market Insights

Lucintel forecasts that migraine-specific abortant triptan is expected to witness higher growth over the forecast period.

Within this market, online pharmacies is expected to witness the higher growth.

North America is expected to witness the highest growth over the forecast period.

Features of the Global Post-Traumatic Headache Market

Market Size Estimates: Post-traumatic headache market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Post-traumatic headache market size by drug type, distribution channel, route of administration, and region in terms of value ($B).

Regional Analysis: Post-traumatic headache market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different drug types, distribution channels, route of administration, and regions for the post-traumatic headache market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the post-traumatic headache market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the growth forecast for post-traumatic headache market?

Answer: The global post-traumatic headache market is expected to grow with a CAGR of 4.3% from 2024 to 2030.

Q2. What are the major drivers influencing the growth of the post-traumatic headache market?

Answer: The major drivers for this market are rising prevalence of traumatic brain injuries, creation of novel treatment alternatives and increasing recognition of PTH.

Q3. What are the major segments for post-traumatic headache market?

Answer: The future of the post-traumatic headache market looks promising with opportunities in the hospital pharmacies, retail pharmacies, and online pharmacies markets.

Q4. Who are the key post-traumatic headache market companies?

Answer: Some of the key post-traumatic headache companies are as follows:

  • Novartis
  • Johnson & Johnson Health Care Systems
  • Impax Laboratories
  • AstraZeneca
  • Grunenthal
  • GlaxoSmithKline
  • Glenmark Pharmaceutical
  • Pfizer
  • Merck & Co
  • Aralez Pharmaceuticals

Q5. Which post-traumatic headache market segment will be the largest in future?

Answer: Lucintel forecasts that oral is expected to witness the highest growth over the forecast period.

Q6. In post-traumatic headache market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness the highest growth over the forecast period.

Q.7 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the post-traumatic headache market by drug type (anti-inflammatory drug, acetylsalicylic acid, acetaminophen, and migraine-specific abortant triptan), distribution channel (hospital pharmacies, retail pharmacies, and online pharmacies), route of administration (oral and injectable), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Post-Traumatic Headache Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Post-Traumatic Headache Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Post-Traumatic Headache Market by Drug Type
    • 3.3.1: Anti-Inflammatory Drug
    • 3.3.2: Acetylsalicylic Acid
    • 3.3.3: Acetaminophen
    • 3.3.4: Migraine-Specific Abortant Triptan
  • 3.4: Global Post-Traumatic Headache Market by Distribution Channel
    • 3.4.1: Hospital Pharmacies
    • 3.4.2: Retail Pharmacies
    • 3.4.3: Online Pharmacies
  • 3.5: Global Post-Traumatic Headache Market by Route of Administration
    • 3.5.1: Oral
    • 3.5.2: Injectable

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Post-Traumatic Headache Market by Region
  • 4.2: North American Post-Traumatic Headache Market
    • 4.2.1: North American Post-Traumatic Headache Market by Drug Type: Anti-Inflammatory Drug, Acetylsalicylic Acid, Acetaminophen, and Migraine-Specific Abortant Triptan
    • 4.2.2: North American Post-Traumatic Headache Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Post-Traumatic Headache Market
    • 4.3.1: European Post-Traumatic Headache Market by Drug Type: Anti-Inflammatory Drug, Acetylsalicylic Acid, Acetaminophen, and Migraine-Specific Abortant Triptan
    • 4.3.2: European Post-Traumatic Headache Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Post-Traumatic Headache Market
    • 4.4.1: APAC Post-Traumatic Headache Market by Drug Type: Anti-Inflammatory Drug, Acetylsalicylic Acid, Acetaminophen, and Migraine-Specific Abortant Triptan
    • 4.4.2: APAC Post-Traumatic Headache Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Post-Traumatic Headache Market
    • 4.5.1: ROW Post-Traumatic Headache Market by Drug Type: Anti-Inflammatory Drug, Acetylsalicylic Acid, Acetaminophen, and Migraine-Specific Abortant Triptan
    • 4.5.2: ROW Post-Traumatic Headache Market by Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Post-Traumatic Headache Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Post-Traumatic Headache Market by Distribution Channel
    • 6.1.3: Growth Opportunities for the Global Post-Traumatic Headache Market by Route of Administration
    • 6.1.4: Growth Opportunities for the Global Post-Traumatic Headache Market by Region
  • 6.2: Emerging Trends in the Global Post-Traumatic Headache Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Post-Traumatic Headache Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Post-Traumatic Headache Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: Johnson & Johnson Health Care Systems
  • 7.3: Impax Laboratories
  • 7.4: AstraZeneca
  • 7.5: Grunenthal
  • 7.6: GlaxoSmithKline
  • 7.7: Glenmark Pharmaceutical
  • 7.8: Pfizer
  • 7.9: Merck & Co
  • 7.10: Aralez Pharmaceuticals